© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Scientists didn’t discover dasatinib overnight. Decades spent cracking the genetic code behind chronic myeloid leukemia (CML) led researchers to the pivotal Philadelphia chromosome, the product of swapped genetic material. This chromosomal mess cooked up a mutant, always-on tyrosine kinase that locked blood cells in hyperdrive. After imatinib scored the first targeted blow against this rogue protein, cancer teams worldwide searched for stronger, more versatile tools. Bristol-Myers Squibb chemists dug deep into the kinase world to engineer a molecule capable of beating mutant forms that resisted earlier treatments. Dasatinib gained U.S. FDA approval in 2006 for use in CML, adding hope for patients running low on options after standard therapies ran their course. Since then, many physicians have seen the difference dasatinib can make as a second-line and sometimes frontline treatment for aggressive blood cancers.
Dasatinib, sold most widely as Sprycel, comes as a white-to-off-white tablet with doses usually ranging between 20 mg and 140 mg. Its key feature is its ability to inhibit multiple types of tyrosine kinases, not just the notorious BCR-ABL fusion protein. That broad action helps control cancer cells that adapt to older drugs. Clinics stock dasatinib both in single-patient prescription bottles and blister packs for safer handling. The FDA label emphasizes its use in adults and children diagnosed with Philadelphia chromosome-positive CML and acute lymphoblastic leukemia (Ph+ ALL).
With a molecular weight hovering near 488 g/mol, dasatinib appears as fine, white crystalline powder. Its chemical formula is C22H26ClN7O2S, and it dissolves enough in dimethyl sulfoxide or methanol for most lab uses. Water solubility stays low—less than 0.1 mg/mL at room temperature. This limited solubility means formulation scientists work hard to create tablets that ensure steady absorption in the gut. Chemically, dasatinib contains a thiazole ring, a pyrimidine scaffold, and a terminal piperazine group. Researchers note its strong performance in acidic environments that mimic the stomach, so patients with more alkaline conditions from antacids or proton pump inhibitors might need stricter monitoring.
Every bottle of dasatinib tablets spells out the dose strength, National Drug Code (NDC), manufacturer, and expiration date. Package inserts warn of potential risks, especially bleeding, fluid retention, and pulmonary arterial hypertension. Patents cover several polymorphic crystal forms, and the major regulators require tablets to meet rigorous standards for content uniformity and dissolution. Pharmacy records also track batch numbers and lot codes to aid rapid recalls if problems ever arise. These safeguards serve a purpose: Dasatinib mistakes can lead to life-threatening side effects.
The road to a pure, potent dasatinib batch starts with condensation of 2-chloro-6-methylpyrimidin-4-amine and 2-aminothiazole, followed by coupling with 4-(2-hydroxyethyl)-1-piperazine. Process engineers optimize everything from pH to reaction temperature, pushing for maximum conversion and minimal impurities. Final product undergoes multi-step crystallization and filtration to weed out any leftover solvents or byproducts. Rigorous analytical testing, including HPLC and LC-MS, sets the bar high for each batch released.
Dasatinib’s thiazole and pyrimidine rings offer chemists several ways to tweak the molecule. In labs, researchers use substitutions and modifications to test analogues with altered selectivity or metabolism. Derivatization can open the door to new kinase inhibition profiles or better pharmacokinetics. The piperazine end group allows further tuning for solubility. These experiments teach scientists where dasatinib excels and where its chemistry falls short.
Beyond its most common trade name Sprycel, dasatinib appears on research shelves as BMS-354825, Bristol-Myers Squibb’s project code before approval. Sometimes catalogues list it by its CAS number, 302962-49-8. Generics out of patent protection carry names like Dasanat, Dasakast, and Xovoltib in various markets. Chemists keep a library of these aliases to avoid costly ordering mistakes—one wrong digit, and you end up with a different kinase inhibitor altogether.
Handling dasatinib calls for solid safety habits. Workers in synthesis labs wear goggles, N95 respirators, and nitrile gloves due to its dust hazard. Trained personnel oversee weighing and tableting using contained systems and HEPA-filtered hoods. Pharmacies send home clear instructions: Swallow tablets whole, avoid breaking or crushing, and keep out of reach of children. Hospitals track every dose, especially for pregnant workers, as animal studies show possible fetal risk. Environmental teams follow waste disposal protocols—unused pills and contaminated materials never hit the regular trash. These rules matter as even tiny accidental exposures could harm sensitive populations.
Dasatinib’s reach goes far beyond just CML. Doctors prescribe it for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and for CML cases that lose response or can’t tolerate other kinase inhibitors. Since it crosses the blood-brain barrier, rare reports note its use in central nervous system leukemia, although off-label and with close monitoring. Research trials examine dasatinib in solid tumors, myelofibrosis, and even some rare pediatric cancers. Lab teams use it for kinase pathway studies, mapping out resistance mutations for new generations of anti-cancer drugs.
Ongoing research digs into dasatinib’s role against resistance mutations. Some teams experiment with combining dasatinib and other targeted drugs to shut down cancer escape routes. Others investigate dosing schedules that cut side effects while preserving cancer-killing power. Scientists run genomic screening on relapse patients to match response patterns with specific BCR-ABL mutations and fine-tune therapy. Long-term survivors provide valuable blood samples that help uncover why some patients achieve durable remissions. Academic groups increasingly turn to dasatinib as a benchmark when designing the next wave of kinase-targeted drugs.
Toxicity does not hide with dasatinib. Common side effects include low platelet counts, anemia, and fluid collection under the skin or around the lungs. Clinical researchers routinely capture data on rare but serious complications such as arterial thrombosis or pulmonary arterial hypertension. Preclinical models point to bone toxicity linked with long-term exposure, prompting extra caution in children. Careful dose-adjustment builds a balance between stopping cancer growth and sparing healthy tissues. Some teams study antidotes or supportive treatments to protect organs at highest risk, making hard-earned remissions safer and more sustainable.
The road ahead for dasatinib stretches into evolving targets and new drug combinations. Research networks test whether dasatinib’s broad kinase blocking can overcome challenges outside the CML and ALL world. Personalized therapy remains the goal, with genetic sequencing revealing exactly who benefits most and for how long. One frontier aims for less daily dosing, replaced by tailored, intermittent schedules to reduce toxicity. Digital tools now plug into trials, tracking patient side effects and outcomes in real time to guide safer use. Drug modification could lead to improved versions with fewer off-target effects and greater power against resistant clones. Decades from now, scientists may look back on dasatinib as an important building block in the story of targeted cancer therapy.
Dasatinib belongs to a class of drugs called tyrosine kinase inhibitors. Physicians prescribe it to people with certain types of leukemia: chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) that have tested positive for the Philadelphia chromosome. This genetic abnormality essentially fuels uncontrolled cell growth, which sets the stage for cancer. I learned about drugs like dasatinib when someone close spent months wrestling through treatments, consults, and tough decisions—trying to keep illness at bay and life on track at the same time.
Philadelphia chromosome-positive leukemias don’t just affect a small group. These conditions disrupt lives for thousands every year. Before targeted options like dasatinib arrived, many faced slim odds. Now, many live longer, better-quality lives because one pill helps disrupt cancer’s plans right at a molecular level. For folks weighing difficult choices, that alone brings hope into reach.
Cancer cells exposed to dasatinib lose the relentless push to multiply. By blocking specific signals that drive the Philadelphia chromosome, the medicine slows, or in many cases, stops cancer growth. The Food and Drug Administration approved dasatinib after solid clinical evidence showed genuine benefits in survival rates. Studies posted in top journals confirm its value, including research published by the American Society of Hematology and the National Institutes of Health.
I have seen—and heard from—families worried about access. Dasatinib, like many cancer pills, comes at a steep price. Insurance coverage eases the burden for some. For others, the sticker shock means relying on patient assistance programs or working through appeals. The work of doctors, nonprofit groups, and patient advocates who help negotiate or subsidize costs can mean the difference between interruption and continuity of treatment. These efforts feel lifelines for many, not luxuries.
Dasatinib is powerful. It can bring tough side effects: low blood cell counts, fluid buildup, infections, or fatigue often join the mix. Oncologists closely monitor bloodwork and symptoms before adjusting doses or adding other meds. Speaking personally, the day-to-day with a loved one on these drugs involves tracking every cough, every ounce of strength gained or lost, and asking plenty of questions at checkups. No two patients respond the same, so having reliable access to information and support matters deeply. Web resources like the Leukemia & Lymphoma Society often provide much-needed clarity and community for families going through the same struggles.
We still face gaps. Rural areas and under-resourced clinics sometimes lack current training about new therapies. Time and again, I’ve watched people travel hours just to get the right test or prescription refilled. Telemedicine and partnerships between major cancer centers and community hospitals could help close some of these divides. Educating both health workers and patients on what to watch for—and how to advocate for themselves—starts to level the field.
Dasatinib’s story offers a window into how far leukemia treatment has come. It underlines why vigilance, research, and a steady hand all matter. For many, it means an ordinary day with less fear—one dose at a time.
Dasatinib shows up in cancer clinics because it helps slow down certain blood cancers, especially chronic myeloid leukemia and acute lymphoblastic leukemia with specific mutations. The goal sounds simple: disrupt cancer cell growth without wiping out everything else. Like most cancer medicines, Dasatinib comes with a set of side effects people can’t ignore. Anyone who’s ever walked with a friend or loved one through a new prescription quickly learns that the label warnings turn into real-world experiences. So, talking openly about these side effects can make treatment less mysterious and more manageable.
Fatigue creeps up early. Most people notice they can’t walk as far or do chores like they used to, even on good days. This tiredness doesn’t disappear after a nap, and patients say it tends to linger until doses change or bodies adapt. Dasatinib can also mess with tummy comfort. Nausea and occasional vomiting show up in the first weeks. Some folks switch to bland foods, while others sip electrolyte drinks just to stay hydrated. Diarrhea sometimes follows, making life near a bathroom a new normal.
Headaches and aches in places you didn’t expect join the club soon after treatment starts. Joints and muscles get sore, and this discomfort can slow a person down, even among tough folks who pride themselves on never missing a day of work. As far as numbers go, clinical studies report headache in roughly one out of three patients, with muscle pain not far behind.
Lab work becomes a regular part of life due to how Dasatinib may lower blood cell counts. Doctors look closely at white blood cells, because a dip here leaves patients open to infections they would've once ignored. Platelets and red blood cells may drop too, raising risks of bruising and tiredness that feels different from everyday exhaustion. Every oncology nurse has stories about urging patients to call in fevers or new bleeding rather than "wait it out."
Fluid retention catches some people off guard. Swollen ankles, puffy faces, and extra weight on the scale can mean something more serious, like fluid collecting around the lungs. This kind of swelling changes the sound of a cough or makes it hard to breathe, which often sends patients to the emergency room. Based on research from published sources, up to 28% of patients face some form of fluid build-up. Quick diagnosis means better outcomes, but recognizing early warning signs matters most.
Some people notice rashes or skin changes, but these mostly stay mild. A rare group deal with changes in heart rhythm or symptoms tied to the liver, which prompt checks of the heart and regular liver panels during routine visits. These less common problems demand attention, not panic. Staying honest about new or worsening symptoms helps doctors decide when to press pause or adjust a dose.
No one wants side effects to get in the way of cancer treatment, but ignoring them never ends well. Simple lifestyle tweaks—hydration, rest, raising legs, daily gentle walks—as well as regular communication with care teams drop the risk of serious complications. Most side effects can be managed with time, care, and work between patient and doctor. If the tough days pile up, remember that better tools for handling side effects keep coming, and sharing what you experience shapes better care for everyone.
Watching loved ones navigate cancer treatments pulls you into a world that moves fast and expects families to keep up with detailed routines. Dasatinib, a medication designed to tackle certain types of leukemia, leaves little room for error. It’s often prescribed to those with chronic myeloid leukemia, and doctors stress how following instructions can impact more than just lab results—it can shape whole days, energy levels, and a patient’s hope.
Dasatinib comes as a tablet taken by mouth. In my experience speaking with patients and their families, doctors usually set a strict time—usually once per day, always at about the same hour. Consistency reduces confusion and helps the drug maintain steady levels inside the body. Missing a dose or taking two doses too close together can throw off this balance, making side effects more intense or lowering the drug’s power.
Some medications demand food or fasting, but dasatinib’s directions usually point to swallowing the tablet whole, with or without food. Touching, breaking, or crushing tablets means shifting how it absorbs and works. I constantly remind friends: stick with water and avoid grapefruit or its juice, since it can push dasatinib to unsafe levels.
My conversations with pharmacists and oncologists always come back to vigilance. Blood cell counts, liver health, and new symptoms predict the next move. I’ve seen people grow anxious about bruising or bleeding. Dasatinib affects bone marrow, so patients often know their platelet and white blood cell numbers better than the weather.
On top of daily medication, staying alert to warning signals means calling your doctor about fevers, chest pain, or trouble breathing. Heart and lung worries can creep up, especially in older adults or those with pre-existing conditions. In my view, questions never bother healthcare teams—rapid reporting can save a trip to the emergency room.
The pillbox fills up fast for many people. Dasatinib’s interaction list runs long—antacids, certain antibiotics, and even over-the-counter drugs can change its performance. Doctors always ask for a complete medication list. Forgetting to mention something as common as an antacid can lead to an unexpected trip back to the cancer center.
Supplements bring their own risks. St. John’s Wort can drop dasatinib levels and cut its benefits. I often recommend carrying a current list or photo of all supplements, prescriptions, and vitamins, so it’s easy to share during appointments.
Helping with my father’s medication routine taught me respect for handling dasatinib. These tablets are potent and shouldn’t be handled with bare hands by caregivers or children. Any unused product should go back to the pharmacy rather than the trash can, keeping kids and pets safe from accidental exposure.
Consistency pays off, both in the science and in daily life. If side effects make swallowing a challenge or if scheduling slips, families can reach out and ask for help. Choosing trust over silence opens doors to support. Dasatinib works best with a routine, a little teamwork, and a willingness to speak up at every step. That lesson stays with me.
Dasatinib treats certain types of leukemia. It works by blocking signals in the cancer cells that help them grow. This is life-changing medicine for thousands who need cancer therapy to work without surprises. Yet, the big thing that doesn’t always make headlines is how many common drugs and supplements can change how dasatinib works—or even make it riskier.
Through years of talking with doctors, pharmacists, and survivors, I’ve seen medication lists that run a mile long. People often add a medicine or a supplement and don’t realize it can bump heads with their leukemia medication. Oncologists push for honesty: tell them about every pill you swallow, including herbal teas and over-the-counter cold meds.
One of the first roadblocks: acid-reducing drugs. Many people take antacids, proton pump inhibitors like omeprazole, or even H2 blockers like ranitidine for heartburn. Dasatinib needs stomach acid for the body to absorb it properly. If you reduce that acid with these popular remedies, less dasatinib gets into your bloodstream. That means your treatment may not work as well. Doctors often have to reschedule doses or switch antacids to a simple, short-acting type so the medicine stands a chance.
Beyond heartburn pills, other drugs mess with the liver enzymes that process dasatinib. The CYP3A4 enzyme breaks down dasatinib in the liver. Drugs that block or ramp up this enzyme can swing dasatinib’s blood levels way too high (risking side effects) or way too low (risking cancer relapse). Common offenders include certain antibiotics (like clarithromycin), antifungal agents (such as ketoconazole), anti-seizure drugs (like phenytoin), and even grapefruit juice. Yes, grapefruit juice. Most people don’t ask about fruit, but even one glass can tangle up your dosing.
Mixing dasatinib with the wrong medications can make you bleed more easily or lower your blood cell counts. Some meds also heighten the odds of irregular heart rhythms (QT prolongation on EKG). People living with cancer face more than enough already. Extra trips to the emergency room because of a careless mix-up? No one needs that.
So, what’s the fix? Honest conversations with both pharmacists and doctors are a must. Every person’s prescription list looks different, and drug interactions aren’t rare science fiction. Complete medication reviews, right from the start, save trouble months down the road. Bringing a handwritten list to your appointments, keeping it up to date, and making sure every provider has your latest info makes it much less likely that something slips through the cracks.
Clinics with electronic prescribing systems often flag dangerous combos, but I’ve seen patients who split care between walk-in clinics, specialists, and traditional healers. No computer system connects everything yet. You really are your own best safety net.
In my circles, the people who do best on cancer therapies seem to be the ones who check, double-check, and then ask one more time before adding new medications or supplements. Plain language helps: ask your pharmacist, “Will this mix OK with my dasatinib?” If you get a rushed answer, ask again.
Researchers, too, keep digging. Even with FDA labels and official warnings, new interactions slip in when new therapies hit the market or when people turn to natural remedies they hope will help them feel better. Cancer care always changes, and so does the list of possible risks. It’s less about memorizing every single interaction and more about keeping the lines of communication open—and not assuming any pill is harmless just because it’s on a pharmacy shelf or comes from a health food store.
Dasatinib saves lives. The right support, smart monitoring, and no-fear questions make those lives healthier and longer.
Dasatinib belongs to a group of drugs called tyrosine kinase inhibitors. Doctors use it mostly for fighting certain types of leukemia, especially chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It helps slow or stop cancer cell growth. Powerful, yes, but not for everyone.
If someone has ever had an allergic reaction to dasatinib, they must steer clear. Severe reactions bring on trouble breathing, rashes, swelling, sometimes even life-threatening symptoms. That risk outweighs the benefit every time. It pays to let doctors know about every past drug allergy, even if the reaction happened a long time ago.
Pregnancy and dasatinib together create a rough situation. Studies show that this drug crosses the placenta and causes harm to a developing baby, sometimes even death. Birth defects and miscarriage risks climb if the drug enters a pregnant person’s system. Those who could get pregnant need reliable birth control while on dasatinib, and doctors typically stress a pregnancy test before treatment starts. I’ve seen patients become anxious about the risks, and those feelings make an open, honest conversation even more important.
Doctors run liver and heart tests before starting dasatinib for a reason. The liver processes this drug. A damaged liver means it struggles to handle dasatinib, leading to higher concentrations in the blood. People with significant liver trouble face more dangerous side effects. On the heart side, dasatinib can cause abnormal heart rhythms (QT prolongation) and worsen heart failure. My own aunt’s heart condition kept her away from many medications—watching her weigh risk versus reward was stressful every time. Folks with a heart history deserve cautious care and a treatment plan their heart can handle.
Dasatinib interacts with a list of other medicines, especially those processed by the liver’s CYP3A4 enzymes. Some examples are St. John’s wort, certain anti-seizure drugs, and strong antibiotics or antifungals. Mixing these with dasatinib can raise or lower its levels unpredictably, sometimes causing life-threatening problems. Grapefruit juice, of all things, messes with the same enzyme. Telling the care team about all supplements, over-the-counter drugs, and drinks helps them keep things safe.
Dasatinib use in kids only fits under tight medical supervision. Little bodies process drugs differently. Long-term effects on growth and development remain hazy. The oldest patients also break down drugs more slowly. Higher risk of side effects comes with age, plus other health issues show up more often.
Low platelets mean higher risk for bleeding, and dasatinib makes this worse. People starting the drug ought to have regular blood tests. Doctors might pause or lower doses for those with dangerously low platelets. Bleeding worries seem small until someone sees a bruise that won’t heal or experiences spontaneous nosebleeds.
Doctors expect patients to ask questions. If something seems off, or if life circumstances change—illness, new medications, or even supplements—bringing it up helps everyone make sure the treatment is safe and effective. Pharmacists play a role, too. They can flag interactions and explain instructions, filling in the details when clinic visits run short. Informed choices protect health and offer a sense of control in uncertain times.
| Names | |
| Preferred IUPAC name | N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide |
| Other names |
Sprycel BMS-354825 |
| Pronunciation | /daˈsætɪnɪb/ |
| Identifiers | |
| CAS Number | 302962-49-8 |
| 3D model (JSmol) | `3D model (JSmol)` of Dasatinib as string: ``` CN1CCN(C1)C(=O)C2=NC3=C(N2)C=CC(=C3)C(=O)NC4=CC=CC=C4Cl ``` This is the SMILES string representation suitable for loading a 3D model in JSmol or similar cheminformatics tools. |
| Beilstein Reference | 4782202 |
| ChEBI | CHEBI:49375 |
| ChEMBL | CHEMBL1421 |
| ChemSpider | 24763611 |
| DrugBank | DB01254 |
| ECHA InfoCard | ECHA InfoCard: "100000749362 |
| EC Number | 4-kinase inhibitor |
| Gmelin Reference | 107852 |
| KEGG | D08904 |
| MeSH | D034945 |
| PubChem CID | 3062316 |
| RTECS number | QT5280950 |
| UNII | 3ZC5LHG2WW |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C22H26ClN7O2S |
| Molar mass | 488.01 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.42 g/cm3 |
| Solubility in water | Practically insoluble |
| log P | 1.89 |
| Vapor pressure | 2.45E-28 mmHg at 25°C |
| Acidity (pKa) | pKa = 6.8 |
| Basicity (pKb) | 3.1 |
| Magnetic susceptibility (χ) | -27.3e-6 cm³/mol |
| Dipole moment | 3.2 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 354.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -209.6 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -7851.6 kJ/mol |
| Pharmacology | |
| ATC code | L01EA02 |
| Hazards | |
| Main hazards | May cause cancer, organ damage, and is harmful if swallowed, inhaled, or absorbed through skin. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS06, GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H332: Harmful if swallowed or if inhaled. |
| Precautionary statements | P201, P202, P261, P264, P270, P280, P308+P313, P405, P501 |
| NFPA 704 (fire diamond) | Health: 3, Flammability: 1, Instability: 0, Special: |
| Flash point | > 315.2 °C |
| Lethal dose or concentration | LD50 (Rat, Oral): > 2,000 mg/kg |
| LD50 (median dose) | 230 mg/kg (oral, rat) |
| PEL (Permissible) | 5 µg/m³ |
| REL (Recommended) | 100 mg daily |
| IDLH (Immediate danger) | NIOSH does not list an IDLH value for Dasatinib. |
| Related compounds | |
| Related compounds |
Bosutinib Imatinib Nilotinib Ponatinib Sunitinib |
